Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

Preferences in MS Therapy: White Paper and Literature Review

Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals